106 related articles for article (PubMed ID: 21585434)
1. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival.
Lenhard M; Lennerová T; Ditsch N; Kahlert S; Friese K; Mayr D; Jeschke U
Histopathology; 2011 May; 58(6):990-4. PubMed ID: 21585434
[No Abstract] [Full Text] [Related]
2. [Survival of patients with ovarian cancer in the Ul'ianovsk Region, 1999-2005].
Antoneeva II
Vopr Onkol; 2007; 53(4):393-5. PubMed ID: 17969399
[No Abstract] [Full Text] [Related]
3. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
4. Prognostic analysis of ovarian cancer associated with endometriosis.
Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
[TBL] [Abstract][Full Text] [Related]
7. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
Nasioudis D; Chapman-Davis E; Witkin SS; Holcomb K
Gynecol Oncol; 2017 Feb; 144(2):414-419. PubMed ID: 27908528
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
11. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
[TBL] [Abstract][Full Text] [Related]
12. GATA6: a new predictor for prognosis in ovarian cancer.
Shen W; Niu N; Lawson B; Qi L; Zhang J; Li T; Zhang H; Liu J
Hum Pathol; 2019 Apr; 86():163-169. PubMed ID: 30633927
[TBL] [Abstract][Full Text] [Related]
13. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Rosen DG; Yang G; Cai KQ; Bast RC; Gershenson DM; Silva EG; Liu J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):632-7. PubMed ID: 15701850
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
[TBL] [Abstract][Full Text] [Related]
15. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
16. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
Kieback DG; Press MF; McCamant SK; Atkinson EN; Möbus VJ; Runnebaum IB; Kreienberg R; Jones LA
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):189-94. PubMed ID: 7789706
[TBL] [Abstract][Full Text] [Related]
18. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
[TBL] [Abstract][Full Text] [Related]
19. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
20. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
